No Data
No Data
No Data
No Data
No Data
HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price target.
BenzingaApr 22 06:40 ET
Poseida Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 890.1% HC Wainwright & Co. → $20 Reiterates Buy → Buy 03/08/2024 890.1% HC Wainwright & Co. → $
BenzingaApr 22 06:39 ET
Express News | Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27TH Annual Meeting
Moomoo 24/7Apr 18 08:00 ET
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE), Poseida Therapeutics (PSTX) and Align Tech (ALGN)
TipRanksApr 18 07:10 ET
Poseida Therapeutics: A Strong Buy on Innovative Gene Therapy Advancements and Strategic Focus
TipRanksApr 18 03:55 ET
Poseida Therapeutics Shares Genetic Medicine R&D Insights
TipRanksApr 17 09:32 ET
No Data
No Data